patient compliance for their new protease inhibitor, Norvir (ritonavir)

Abbott is sending out letters emphasizing patient compliance for their new protease inhibitor, Norvir (ritonavir).

The problem is that patients starting Norvir often develop nausea...diarrhea...and peripheral neuropathy. This may tempt them to stop the drug or cut back on the dose.

But maintaining therapeutic levels of Norvir is crucial...to suppress HIV and prevent the rapid development of resistance.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote